PRPO Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio—Forward 15.43
EPS (TTM)$-0.450.0% YoY
Profit margin-3.6%HEALTHCARE
Market cap$39.8MMicro cap
Valuation
- Forward P/E
- 15.43
- PEG ratio
- 0.00
- P/B
- 2.80
- P/S (TTM)
- 1.54
- EV/EBITDA
- 43.52
Profitability & growth
- ROE (TTM)
- -7.1%
- Operating margin
- -21.3%
- Revenue growth YoY
- 36.2%
- Dividend yield
- —
- Beta
- 1.38
Last earnings
May 18, 2026 · Reported $-0.81
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Precipio Inc
Company profilePrecipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. The company is headquartered in New Haven, Connecticut.
Classification
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 4 SCIENCE PARK, NEW HAVEN, CT
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$39.8M
Shares outstanding$1.8M
52W high$33.63
52W low$10.52
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent